vs
Core Natural Resources, Inc.（CNR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Core Natural Resources, Inc.的季度营收约是Revvity的1.4倍（$1.0B vs $772.1M），Revvity净利率更高（12.7% vs -7.6%，领先20.3%），Core Natural Resources, Inc.同比增速更快（81.8% vs 5.9%），Revvity自由现金流更多（$161.8M vs $26.0M），过去两年Core Natural Resources, Inc.的营收复合增速更高（38.1% vs 9.0%）
Arch Resources（原阿奇煤炭）曾是美国煤炭开采加工企业，为美国第二大煤炭供应商，仅次于皮博迪能源，2011年占据美国国内15%的市场份额，主营低硫烟煤、次烟煤的开采、加工与销售，客户以发电企业为主。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CNR vs RVTY — 直观对比
营收规模更大
CNR
是对方的1.4倍
$772.1M
营收增速更快
CNR
高出75.9%
5.9%
净利率更高
RVTY
高出20.3%
-7.6%
自由现金流更多
RVTY
多$135.8M
$26.0M
两年增速更快
CNR
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $772.1M |
| 净利润 | $-79.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | -9.3% | 14.5% |
| 净利率 | -7.6% | 12.7% |
| 营收同比 | 81.8% | 5.9% |
| 净利润同比 | -356.3% | 3.9% |
| 每股收益（稀释后） | $-1.51 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CNRRVTY
| Q4 25 | $1.0B | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $573.6M | $729.4M | ||
| Q3 24 | $553.4M | $684.0M | ||
| Q2 24 | $490.7M | $691.7M | ||
| Q1 24 | $546.7M | $649.9M |
净利润CNRRVTY
| Q4 25 | $-79.0M | $98.4M | ||
| Q3 25 | $31.6M | $46.7M | ||
| Q2 25 | $-36.6M | $53.9M | ||
| Q1 25 | $-69.3M | $42.2M | ||
| Q4 24 | $30.8M | $94.6M | ||
| Q3 24 | $95.6M | $94.4M | ||
| Q2 24 | $58.1M | $55.4M | ||
| Q1 24 | $101.9M | $26.0M |
毛利率CNRRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CNRRVTY
| Q4 25 | -9.3% | 14.5% | ||
| Q3 25 | -1.2% | 11.7% | ||
| Q2 25 | -1.7% | 12.6% | ||
| Q1 25 | -5.3% | 10.9% | ||
| Q4 24 | 6.6% | 16.3% | ||
| Q3 24 | 21.2% | 14.3% | ||
| Q2 24 | 14.6% | 12.4% | ||
| Q1 24 | 22.7% | 6.8% |
净利率CNRRVTY
| Q4 25 | -7.6% | 12.7% | ||
| Q3 25 | 3.2% | 6.7% | ||
| Q2 25 | -3.3% | 7.5% | ||
| Q1 25 | -6.8% | 6.4% | ||
| Q4 24 | 5.4% | 13.0% | ||
| Q3 24 | 17.3% | 13.8% | ||
| Q2 24 | 11.8% | 8.0% | ||
| Q1 24 | 18.6% | 4.0% |
每股收益（稀释后）CNRRVTY
| Q4 25 | $-1.51 | $0.86 | ||
| Q3 25 | $0.61 | $0.40 | ||
| Q2 25 | $-0.70 | $0.46 | ||
| Q1 25 | $-1.38 | $0.35 | ||
| Q4 24 | $1.04 | $0.77 | ||
| Q3 24 | $3.22 | $0.77 | ||
| Q2 24 | $1.96 | $0.45 | ||
| Q1 24 | $3.39 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $432.2M | $919.9M |
| 总债务越低越好 | $354.2M | — |
| 股东权益账面价值 | $3.7B | $7.3B |
| 总资产 | $6.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.10× | — |
8季度趋势，按日历期对齐
现金及短期投资CNRRVTY
| Q4 25 | $432.2M | $919.9M | ||
| Q3 25 | $444.7M | $931.4M | ||
| Q2 25 | $413.2M | $991.8M | ||
| Q1 25 | $388.5M | $1.1B | ||
| Q4 24 | $460.2M | $1.2B | ||
| Q3 24 | $331.7M | $1.2B | ||
| Q2 24 | $216.1M | $2.0B | ||
| Q1 24 | $172.6M | $1.7B |
总债务CNRRVTY
| Q4 25 | $354.2M | — | ||
| Q3 25 | $334.5M | — | ||
| Q2 25 | $334.0M | — | ||
| Q1 25 | $329.8M | — | ||
| Q4 24 | $94.8M | — | ||
| Q3 24 | $83.7M | — | ||
| Q2 24 | $184.9M | — | ||
| Q1 24 | $185.5M | — |
股东权益CNRRVTY
| Q4 25 | $3.7B | $7.3B | ||
| Q3 25 | $3.8B | $7.4B | ||
| Q2 25 | $3.8B | $7.6B | ||
| Q1 25 | $3.9B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.5B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B | ||
| Q1 24 | $1.4B | $7.8B |
总资产CNRRVTY
| Q4 25 | $6.1B | $12.2B | ||
| Q3 25 | $6.2B | $12.1B | ||
| Q2 25 | $6.2B | $12.4B | ||
| Q1 25 | $6.3B | $12.4B | ||
| Q4 24 | $2.9B | $12.4B | ||
| Q3 24 | $2.8B | $12.8B | ||
| Q2 24 | $2.7B | $13.4B | ||
| Q1 24 | $2.7B | $13.4B |
负债/权益比CNRRVTY
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.09× | — | ||
| Q2 25 | 0.09× | — | ||
| Q1 25 | 0.08× | — | ||
| Q4 24 | 0.06× | — | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $107.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $26.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 2.5% | 21.0% |
| 资本支出强度资本支出/营收 | 7.8% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $21.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CNRRVTY
| Q4 25 | $107.3M | $182.0M | ||
| Q3 25 | $87.9M | $138.5M | ||
| Q2 25 | $220.2M | $134.3M | ||
| Q1 25 | $-109.6M | $128.2M | ||
| Q4 24 | $121.3M | $174.2M | ||
| Q3 24 | $161.3M | $147.9M | ||
| Q2 24 | $116.3M | $158.6M | ||
| Q1 24 | $77.5M | $147.6M |
自由现金流CNRRVTY
| Q4 25 | $26.0M | $161.8M | ||
| Q3 25 | $38.6M | $120.0M | ||
| Q2 25 | $131.0M | $115.5M | ||
| Q1 25 | $-174.5M | $112.2M | ||
| Q4 24 | $80.5M | $149.8M | ||
| Q3 24 | $121.9M | $125.6M | ||
| Q2 24 | $60.9M | $136.6M | ||
| Q1 24 | $35.1M | $129.7M |
自由现金流率CNRRVTY
| Q4 25 | 2.5% | 21.0% | ||
| Q3 25 | 3.9% | 17.2% | ||
| Q2 25 | 11.9% | 16.0% | ||
| Q1 25 | -17.1% | 16.9% | ||
| Q4 24 | 14.0% | 20.5% | ||
| Q3 24 | 22.0% | 18.4% | ||
| Q2 24 | 12.4% | 19.7% | ||
| Q1 24 | 6.4% | 20.0% |
资本支出强度CNRRVTY
| Q4 25 | 7.8% | 2.6% | ||
| Q3 25 | 4.9% | 2.6% | ||
| Q2 25 | 8.1% | 2.6% | ||
| Q1 25 | 6.4% | 2.4% | ||
| Q4 24 | 7.1% | 3.4% | ||
| Q3 24 | 7.1% | 3.3% | ||
| Q2 24 | 11.3% | 3.2% | ||
| Q1 24 | 7.7% | 2.7% |
现金转化率CNRRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 2.78× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 3.94× | 1.84× | ||
| Q3 24 | 1.69× | 1.57× | ||
| Q2 24 | 2.00× | 2.87× | ||
| Q1 24 | 0.76× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CNR
| Other | $397.4M | 38% |
| Power Generation | $376.5M | 36% |
| PRB | $183.0M | 18% |
| Metallurgical | $42.0M | 4% |
| Industrial | $34.1M | 3% |
| Terminal Revenue | $6.4M | 1% |
| Other Revenue | $3.0M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
